Halyard Health, Inc. is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections. The Company address healthcare needs, such as reducing the use of opioids, while helping patients move from surgery to recovery. The Medical Devices segment's products include post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems and enteral feeding tubes. The S&IP segment includes product offerings, such as sterilization wrap, surgical drapes and gowns, facial protection, protective apparel and medical exam gloves.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Symbol: NYSE:HYH
- CUSIP: N/A
- Web: www.halyardhealth.com
- Market Cap: $1.99 billion
- Outstanding Shares: 46,792,000
- 50 Day Moving Avg: $40.53
- 200 Day Moving Avg: $38.98
- 52 Week Range: $31.59 - $43.78
Sales & Book Value:
- Trailing P/E Ratio: 40.89
- Foreward P/E Ratio: 20.06
- P/E Growth: 4.55
- Annual Revenue: $1.6 billion
- Price / Sales: 1.24
- Book Value: $24.77 per share
- Price / Book: 1.72
- EBIDTA: $182 million
- Net Margins: 3.06%
- Return on Equity: 8.29%
- Return on Assets: 4.44%
- Debt-to-Equity Ratio: 0.50%
- Current Ratio: 2.03%
- Quick Ratio: 1.11%
- Average Volume: 346,122 shs.
- Beta: 1.78
- Short Ratio: 11.18
Frequently Asked Questions for Halyard Health (NYSE:HYH)
What is Halyard Health's stock symbol?
Halyard Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HYH."
How were Halyard Health's earnings last quarter?
Halyard Health, Inc. (NYSE:HYH) released its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.51 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.37 by $0.14. The business had revenue of $399.20 million for the quarter, compared to the consensus estimate of $399.16 million. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The company's quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the firm earned $0.45 earnings per share. View Halyard Health's Earnings History.
When will Halyard Health make its next earnings announcement?
What guidance has Halyard Health issued on next quarter's earnings?
Halyard Health updated its FY18 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of $1.85-2.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.04.
Where is Halyard Health's stock going? Where will Halyard Health's stock price be in 2017?
4 analysts have issued 12-month target prices for Halyard Health's stock. Their predictions range from $38.00 to $45.00. On average, they expect Halyard Health's stock price to reach $41.67 in the next year. View Analyst Ratings for Halyard Health.
What are analysts saying about Halyard Health stock?
Here are some recent quotes from research analysts about Halyard Health stock:
- 1. According to Zacks Investment Research, "Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. " (7/12/2017)
- 2. Stifel Nicolaus analysts commented, "HYH closed 2016 with its fourth consecutive quarter of sales and EPS upside relative to both Consensus and management guidance. After a more difficult than expected first-year (2015) post-spin, in 2016, the company's transformation took clearer shape and was highlighted by: accretive M&A, a positive mix shift to the more profitable Medical Device franchise (38% of sales; 64% of operating profit), successful re-negotiations of material GPO contracts, significant organic cost-savings and stepped-up investments, all with significantly improved cash flow generation ($100M+ guide vs. $160M actual). We continue to believe HYH has further price appreciation potential ahead as '2016-like' thematic drivers continue playing out over the next 12-24 months. Still, we acknowledge that HYH shares (+56% TTM vs. S&P500: +23%) trading at 20x 2018E EPS (vs. large cap ~18x) could "pause" here as the stock absorbs the recent out-performance and the next wave of potentially positive catalysts becomes more visible. Yet to be realized sales, margin, and EPS-enhancing catalysts could include: IT cost savings, better S&IP pricing, more normal nitrile pricing and most important, further accretive M&A opportunities. Company-specific 2017 headwinds could include: more intense commodity price inflation, stepped up On-Q competition, and still uncertain macro tax-related legislation. For us, the bottom line is that HYH remains a positive long-term transformation story that is still in 'early innings' with significant opportunity both organically and through acquisitions to leverage earnings. We rate HYH Buy and raise our TP to $45 (from $38)." (2/28/2017)
Who are some of Halyard Health's key competitors?
Some companies that are related to Halyard Health include Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), NuVasive (NUVA), LivaNova PLC (LIVN), Neogen Corporation (NEOG), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Inogen (INGN), MiMedx Group (MDXG), CONMED Corporation (CNMD), OraSure Technologies (OSUR), K2M Group Holdings (KTWO), Cardiovascular Systems (CSII), Asante Solutions (PUMP), Intersect ENT (XENT), Orthofix International N.V. (OFIX), AtriCure (ATRC) and Cryolife (CRY).
Who are Halyard Health's key executives?
Halyard Health's management team includes the folowing people:
- Robert E. Abernathy, Chairman of the Board
- Joseph F. Woody, Chief Executive Officer, Director
- Steven E. Voskuil, Chief Financial Officer, Senior Vice President
- Christopher M. Lowery, Chief Operating Officer, Senior Vice President
- Rhonda D. Gibby, Chief Human Resource Officer, Senior Vice President
- John W. Wesley, Senior Vice President, General Counsel
- Christopher G. Isenberg, Senior Vice President - Global Supply Chain and Procurement
- Warren J. Machan, Senior Vice President - Business Strategy
- Ronald W. Dollens, Lead Independent Director
- Gary D. Blackford, Independent Director
Who owns Halyard Health stock?
Halyard Health's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.32%), Vanguard Group Inc. (9.03%), Dimensional Fund Advisors LP (6.70%), Goldman Sachs Group Inc. (3.98%), State Street Corp (3.64%) and Paradice Investment Management LLC (3.28%). Company insiders that own Halyard Health stock include Robert E Abernathy and Steven E Voskuil. View Institutional Ownership Trends for Halyard Health.
Who sold Halyard Health stock? Who is selling Halyard Health stock?
Halyard Health's stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Cove Street Capital LLC, Vanguard Group Inc., Gotham Asset Management LLC, Wells Fargo & Company MN, Cornerstone Capital Management Holdings LLC., Convergence Investment Partners LLC and GSA Capital Partners LLP. View Insider Buying and Selling for Halyard Health.
Who bought Halyard Health stock? Who is buying Halyard Health stock?
Halyard Health's stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Northern Trust Corp, Koch Industries Inc., JPMorgan Chase & Co., State Street Corp, Paradice Investment Management LLC and AXA. Company insiders that have bought Halyard Health stock in the last two years include Robert E Abernathy and Steven E Voskuil. View Insider Buying and Selling for Halyard Health.
How do I buy Halyard Health stock?
Shares of Halyard Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halyard Health's stock price today?
MarketBeat Community Rating for Halyard Health (NYSE HYH)MarketBeat's community ratings are surveys of what our community members think about Halyard Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Halyard Health stock can currently be purchased for approximately $42.53.
Consensus Ratings for Halyard Health (NYSE:HYH) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 3 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.75)|
|Consensus Price Target: ||$41.67 (2.03% downside)|
Analysts' Ratings History for Halyard Health (NYSE:HYH)
(Data available from 8/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/3/2017||Deutsche Bank AG||Boost Price Target||Buy||$35.00 -> $42.00||Medium|
|8/3/2017||Stephens||Upgrade||Equal Weight -> Overweight||Medium|
|2/28/2017||Stifel Nicolaus||Boost Price Target||Buy||$38.00 -> $45.00||N/A|
|1/6/2017||JMP Securities||Downgrade||Outperform -> Market Perform||$38.00||N/A|
|12/18/2015||KeyCorp||Initiated Coverage||Sector Weight||N/A|
|10/12/2015||Morgan Stanley||Downgrade||Equal Weight -> Underweight||$27.00||N/A|
Earnings History for Halyard Health (NYSE:HYH)Earnings History by Quarter for Halyard Health (NYSE HYH)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||$0.37||$0.51||$399.16 million||$399.20 million||View||Listen|
|5/2/2017||Q1 2017||$0.43||$0.48||$391.56 million||$395.60 million||View||Listen|
|2/27/2017||Q416||$0.44||$0.50||$401.72 million||$410.00 million||View||Listen|
|11/2/2016||Q316||$0.39||$0.48||$387.64 million||$398.00 million||View||N/A|
|8/3/2016||Q216||$0.36||$0.45||$383.08 million||$400.00 million||View||N/A|
|5/4/2016||Q116||$0.34||$0.53||$369.80 million||$385.00 million||View||N/A|
|2/29/2016||Q415||$0.50||$0.57||$401.96 million||$401.40 million||View||Listen|
|11/3/2015||Q315||$0.47||$0.52||$388.00 million||$390.00 million||View||N/A|
|8/4/2015||Q215||$0.53||$0.52||$401.70 million||$389.30 million||View||N/A|
|5/4/2015||Q1 2015||$0.64||$0.51||$390.00 million||$394.00 million||View||N/A|
|3/4/2015||Q4||$0.75||$1.59||$425.10 million||$439.40 million||View||N/A|
Earnings Estimates for Halyard Health (NYSE:HYH)
2017 EPS Consensus Estimate: $1.80
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Halyard Health (NYSE:HYH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Halyard Health (NYSE:HYH)
Insider Ownership Percentage: 1.30%Insider Trades by Quarter for Halyard Health (NYSE:HYH)
Institutional Ownership Percentage: 90.32%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/4/2015||Robert E Abernathy||CEO||Buy||10,000||$31.06||$310,600.00|| |
|9/1/2015||Steven E Voskuil||CFO||Buy||1,000||$30.00||$30,000.00|| |
Headline Trends for Halyard Health (NYSE:HYH)
Latest Headlines for Halyard Health (NYSE:HYH)
|Halyard Health, Inc. (HYH) Stock Rating Upgraded by BidaskClub|
www.americanbankingnews.com - August 19 at 6:28 PM
|Halyard Health, Inc. (HYH) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - August 12 at 8:34 PM
|Top Ranked Momentum Stocks to Buy for August 8th|
www.zacks.com - August 10 at 12:58 AM
|See what the IHS Markit Score report has to say about Halyard Health Inc.|
finance.yahoo.com - August 9 at 7:54 PM
|Halyard Health: As Shares Surge To 52-Week Highs, Transformation Will Continue - Seeking Alpha|
seekingalpha.com - August 8 at 7:23 PM
|Q4 2017 EPS Estimates for Halyard Health, Inc. Cut by KeyCorp (HYH)|
www.americanbankingnews.com - August 7 at 7:28 AM
|Halyard Health, Inc. (NYSE:HYH) Expected to Post Quarterly Sales of $395.18 Million|
www.americanbankingnews.com - August 5 at 7:08 AM
|Halyard Health, Inc. Announces Second Quarter 2017 Results, Raises Full-Year Adjusted Diluted EPS Outlook|
finance.yahoo.com - August 4 at 7:57 PM
|Investor Network: Halyard Health Inc to Host Earnings Call|
finance.yahoo.com - August 4 at 7:57 PM
|Head-To-Head Comparison: Halyard Health (NYSE:HYH) vs. Integra LifeSciences Holdings Corporation (IART)|
www.americanbankingnews.com - August 4 at 7:52 AM
|Research Analysts Set Expectations for Halyard Health, Inc.'s Q3 2017 Earnings (NYSE:HYH)|
www.americanbankingnews.com - August 4 at 7:42 AM
|Edited Transcript of HYH earnings conference call or presentation 2-Aug-17 1:00pm GMT|
finance.yahoo.com - August 4 at 12:46 AM
|Halyard Health target of 60 Minutes report on allegedly providing faulty surgical gowns to US hospitals; investors ... - Seeking Alpha|
seekingalpha.com - August 3 at 7:44 PM
|Halyard Health's (HYH) CEO Joseph Woody on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha|
seekingalpha.com - August 2 at 8:17 PM
|Halyard tops 2Q profit forecasts|
finance.yahoo.com - August 2 at 8:16 PM
|Halyard Health, Inc. (HYH) Announces Quarterly Earnings Results|
www.americanbankingnews.com - August 2 at 3:02 PM
|Halyard Health, Inc. (HYH) Updates FY18 Earnings Guidance|
www.americanbankingnews.com - August 2 at 9:52 AM
|Halyard Health, Inc. To Webcast Conference Call Discussing Second Quarter 2017 Financial Results - PR Newswire (press release)|
www.prnewswire.com - July 28 at 10:43 PM
|Halyard Health, Inc. To Webcast Conference Call Discussing Second Quarter 2017 Financial Results|
finance.yahoo.com - July 26 at 4:07 PM
|Halyard Health, Inc. (HYH) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - July 18 at 8:47 PM
|$400.37 Million in Sales Expected for Halyard Health, Inc. (NYSE:HYH) This Quarter|
www.americanbankingnews.com - July 14 at 1:24 PM
|Zacks: Brokerages Expect Halyard Health, Inc. (NYSE:HYH) Will Post Earnings of $0.38 Per Share|
www.americanbankingnews.com - July 12 at 4:16 PM
|Halyard Health, Inc. (HYH) Downgraded by BidaskClub to Hold|
www.americanbankingnews.com - July 8 at 6:32 PM
|Halyard Health: Is A Major Divestiture In The Works? - Seeking Alpha - Seeking Alpha|
seekingalpha.com - July 1 at 12:47 AM
|ICU Medical (ICUI) and Halyard Health (HYH) Head to Head Analysis|
www.americanbankingnews.com - June 28 at 6:28 PM
|Halyard Health, Inc. (HYH) Upgraded to Buy at BidaskClub|
www.americanbankingnews.com - June 28 at 6:14 PM
|Corporate News Blog - Halyard Health Views CEO Transition; Robert Abernathy Replaced by Joseph Woody from Acelity|
finance.yahoo.com - June 26 at 7:35 PM
|Halyard Health, Inc. (HYH) Stock Rating Upgraded by TheStreet|
www.americanbankingnews.com - June 25 at 11:40 PM
|Halyard Health Announces CEO Transition - PR Newswire (press release)|
www.prnewswire.com - June 24 at 6:10 PM
|Halyard Health, Inc. (HYH) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - June 23 at 6:34 PM
|Halyard Health (HYH) CEO Robert Abernathy to Retire; Board Appoints Joseph Woody as CEO Successor|
www.streetinsider.com - June 23 at 6:02 PM
|Halyard Health Announces CEO Transition|
finance.yahoo.com - June 23 at 6:02 PM
|Atlanta's Halyard Health names new CEO, who's getting $1M sign-on award|
finance.yahoo.com - June 23 at 6:02 PM
| Analysts Anticipate Halyard Health, Inc. (HYH) Will Post Quarterly Sales of $400.37 Million|
www.americanbankingnews.com - June 18 at 8:55 AM
| Analysts Expect Halyard Health, Inc. (HYH) Will Post Earnings of $0.39 Per Share|
www.americanbankingnews.com - June 16 at 4:42 PM
|ETFs with exposure to Halyard Health, Inc. : June 15, 2017|
finance.yahoo.com - June 15 at 8:02 PM
|Halyard Health explores sale of hospital product unit: sources - Reuters|
www.reuters.com - June 13 at 10:36 PM
|Halyard Health explores sale of hospital product unit: sources|
www.reuters.com - June 12 at 6:26 PM
|Halyard Health explores sale of hospital product unit-sources|
finance.yahoo.com - June 12 at 6:26 PM
|Halyard Health, Inc. breached its 50 day moving average in a Bullish Manner : HYH-US : June 9, 2017|
finance.yahoo.com - June 9 at 9:46 AM
|Halyard Health (HYH) Shares Cross Above 200 DMA|
www.nasdaq.com - June 2 at 7:12 PM
|Halyard Health Inc (HYH) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - May 29 at 6:50 PM
|Halyard Health (HYH) Expands CORGRIP System Product Line - Nasdaq|
www.nasdaq.com - May 24 at 5:38 PM
|Halyard Health (HYH) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow|
seekingalpha.com - May 23 at 5:23 PM
|Halyard Health Introduces Expanded Sizes for CORGRIP* NG/NI Tube Retention System|
finance.yahoo.com - May 22 at 10:57 AM
|Halyard Health (HYH) & Sustainable Solutions Announce Licensing Agreement for Hospital Products from Recycled ... - StreetInsider.com|
www.streetinsider.com - May 19 at 10:21 AM
|Halyard Health (HYH) & Sustainable Solutions Announce Licensing Agreement for Hospital Products from Recycled Sterilization Wrap|
www.streetinsider.com - May 18 at 9:31 AM
|Halyard Health and Sustainable Solutions Enter Licensing Agreement to Create Environmentally Conscious Hospital Products from Recycled Sterilization Wrap|
finance.yahoo.com - May 18 at 9:31 AM
|Halyard Health Adds New Drainage System to Comprehensive Portfolio of Enteral Feeding Products|
finance.yahoo.com - May 16 at 11:14 AM
|Halyard Health, Inc. to Present at Bank of America Merrill Lynch 2017 Healthcare Conference|
finance.yahoo.com - May 11 at 6:25 PM
Halyard Health (HYH) Chart for Sunday, August, 20, 2017